The dramatic stock slump, which puts Novo Nordisk at a historically cheap valuation, reflects investor concern over future sales growth and competition, particularly from rival Eli Lilly & Co.
Novo Nordisk enters the final stretch of 2025 looking almost unrecognizable from the market darling it was just months ago.
The coming year, 2026, is shaping up as a critical operational and financial test. A head-to-head comparative study between Novo Nordisk's CagriSema and Eli Lilly's Zepbound, scheduled for 2026, will ...
Hims & Hers Health has sold off ~40% GLP-1 turbulence, but the core growth story remains intact. Read why HIMS stock is a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback